Lonza and OncoMed sign process development and manufacturing deal

Lonza says it has signed an agreement with OncoMed Pharmaceuticals (Redwood City, CA), a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, for the development and manufacture of OncoMed’s pipeline of anticancer stem-cell therapeutics. Lonza will produce material at its mammalian manufacturing facility at Slough, UK, under the deal. The multiproduct GS system license provides access to Lonza’s GS Gene Expression System and Version 8 Media and Feeds manufacturing platform.   OncoMed’s pipeline is focused on the...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers